Home/Browse by collection/Oncolytic and Local Immunotherapy

Oncolytic and Local Immunotherapy

Section Edited by Howard L. Kaufman, MD, FACS This section focuses on the role of therapeutic agents designed for targeting tumor cells and/or the tumor microenvironment. This includes oncolytic viruses, microbial agents, innate immune agonists, direct and systemically delivered proteins and DNA/RNA products that act within established tumors. Research describing the characterization and basic biology of oncolytic agents and novel delivery systems are encouraged. An emphasis on how novel intra-tumoral directed agents modulate local and systemic host innate and adaptive anti-tumor immunity are of particular interest. In addition, the section welcomes translational and clinical investigation involving new oncolytic immunotherapy agents or those that include an oncolytic approach as part of combination therapeutic regimens.

Showing results 21 - 30 of 100

Sorted by most recent

Neoadjuvant intratumoral influenza vaccine treatment in patients with proficient mismatch repair colorectal cancer leads to increased tumor infiltration of CD8+ T cells and upregulation of PD-L1: a phase 1/2 clinical trial
Mikail Gögenur, Lukas Balsevicius, Mustafa Bulut, Nesibe Colak, Tobias Freyberg Justesen, Anne-Marie Kanstrup Fiehn, Marianne Bøgevang Jensen, Kathrine Høst-Rasmussen, Britt Cappelen, Shruti Gaggar, Asma Tajik, Jawad Ahmad Zahid, Astrid Louise Bjørn Bennedsen, Tommaso Del Buono D’Ondes, Hans RaskovSee the full list of authors

12 May 2023